Breaking News
Investing Pro 0
⏰ React to the Market Faster with Custom, Real-Time News Get Started

Factbox-US government to impose inflation penalties on 27 drugs

Stock Markets Mar 15, 2023 11:46AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration taken June 30, 2018. REUTERS/Russell Boyce/Illustration
 
GILD
+1.57%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PFE
+0.52%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GRFS
-1.15%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ABBV
+1.75%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
KMDA
+1.16%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

(Reuters) - The U.S. government said on Wednesday it will subject 27 drugs to inflation penalties, a move that will require the pharmaceutical companies to pay Medicare rebates if they raise prices at a faster pace than the rise in inflation rate.

    Under the new provisions, the government will start invoicing the companies for the rebates in 2025, but Medicare members will see a reduction in out-of-pocket costs starting April.

Here is a list of the drugs and companies:

DRUG NAME USED FOR MANUFACTURER U.S. NET

SALES IN

2022

Humira Arthritis AbbVie Inc (NYSE:ABBV) $18.62

billion

Yescarta Blood cancer Gilead Sciences (NASDAQ:GILD) $747

Inc million

Padcev Urothelial cancer  Seagen Inc   $451

million

Xiaflex    Peyronie's disease Endo $438.7

International million

Plc 

Tecartus   Blood cancer Gilead Sciences $221

Inc million

Mircera  Anemia  Roche 408 million

Swiss

Francs

($442.66

million) in

global

sales

Fetroja  Serious bladder or Shionogi & Co 7.3 billion

kidney infections Ltd  yen in

in adults Apr-Dec

2022 ($54.6

million)

Fragmin  Treat blood clots  Pfizer Inc (NYSE:PFE) $4 million

Abelcet Invasive fungal Leadiant Data

infections Biosciences unavailable

Akynzeo Prevention of Helsinn Data

chemotherapy-induce Healthcare S.A unavailable

d nausea and

vomiting

Atgam Used after kidney Pfizer Inc Data

transplant to keep unavailable

the body from

rejecting the organ

Aveed Treat low Endo Data

testosterone in International unavailable

adult males Plc

Bicillin Antibiotic Pfizer Inc Data

C-R unavailable

Bicillin Antibiotic Pfizer Inc Data

L-A unavailable

Carnitor Carnitine Leadiant Data

deficiency Biosciences unavailable

Cytogam To prevent a Kamada (NASDAQ:KMDA) Ltd Data

cytomegalovirus unavailable

disease infection

in transplant

patients

Elzonris Rare form of blood Menarini Group Data

cancer unavailable

Flebogamma Treatment for Grifols SA (NASDAQ:GRFS) Data

DIF primary unavailable

immunodeficiency

and autoimmune

disease

Folotyn T-cell lymphoma Acrotech Data

Biopharma LLC unavailable

Leukine Blood cancer Partner Data

Therapeutics unavailable

Minocin To prevent Bausch Health Data

infections in Companies unavailable

hospitalized

patients

Nipent Blood cancer Pfizer Inc Data

unavailable

Rybrevant Lung cancer Johnson & Data

Johnson unavailable

Signifor For the rare Recordati Data

LAR diseases Acromegaly unavailable

and Cushing's

disease

Sylvant Multicentric EUSA Pharma (US) Data

Castleman's disease LLC unavailable

Winrho SDF Bleeding disorder Kamada Ltd 's Data

unavailable

Xipere Eye disease macular Bausch and Data

edema associated Lomb's unavailable

with uveitis

($1 = 0.9217 Swiss francs)

Factbox-US government to impose inflation penalties on 27 drugs
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email